Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Orgenesis Inc (ORGS)

Orgenesis Inc (ORGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,095
  • Shares Outstanding, K 31,877
  • Annual Sales, $ 36,030 K
  • Annual Income, $ -14,890 K
  • 60-Month Beta 1.04
  • Price/Sales 0.84
  • Price/Cash Flow N/A
  • Price/Book 2.06
Trade ORGS with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.91
  • Most Recent Earnings $-0.43 on 11/13/23
  • Latest Earnings Date 04/02/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 147.58%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.39
  • Growth Rate Est. (year over year) +256,253.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6082 +35.15%
on 02/29/24
0.9130 -9.97%
on 03/25/24
+0.1990 (+31.94%)
since 02/28/24
3-Month
0.2500 +228.80%
on 02/09/24
0.9130 -9.97%
on 03/25/24
+0.3200 (+63.75%)
since 12/28/23
52-Week
0.2500 +228.80%
on 02/09/24
1.5000 -45.20%
on 06/30/23
-0.4880 (-37.25%)
since 03/28/23

Most Recent Stories

More News
Orgenesis Achieves Revenue of $7.2 Million for the First Quarter of 2022

GERMANTOWN, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to...

ORGS : 0.8220 (-3.29%)
Orgenesis Led Consortium Awarded €4M European Innovation Council Pathfinder Grant

Focus is to Develop Cost-effective Production of Autologous Induced Pluripotent Stem Cells (iPSCs) using Microfluidic Technologies and Artificial...

ORGS : 0.8220 (-3.29%)
Orgenesis Reports Revenue Growth of 364% for 2021 and Provides Business Update

Orgenesis to host conference call today at 12:00 PM ET...

ORGS : 0.8220 (-3.29%)
Orgenesis reaches next milestone in collaboration with Hospital Infantil Universitario Niño Jesús in Madrid

Orgenesis achieves milestone in the placement of the Orgenesis Mobile Processing Units and Lab (OMPUL) for the development of cell and gene therapies at...

ORGS : 0.8220 (-3.29%)
Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing

Center will expand Orgenesis’ Point of Care (POCare) Platform Capabilities in Maryland...

ORGS : 0.8220 (-3.29%)
Orgenesis Reports 425% Increase in Revenue for the Third Quarter of 2021 Compared to Same Period Last Year

Orgenesis to host conference call today at 8:30AM ET...

ORGS : 0.8220 (-3.29%)
Orgenesis Schedules Third Quarter 2021 Business Update Conference Call

GERMANTOWN, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to...

ORGS : 0.8220 (-3.29%)
Orgenesis Announces Collaboration Agreement with Savicell to License and Deploy its ImmunoBiopsy™ Platform

Goal to accelerate development, QC testing and manufacturing  of Orgenesis’ cell and gene therapy platform

ORGS : 0.8220 (-3.29%)
Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021

LOS ANGELES, CA / ACCESSWIRE / August 16, 2021 / The SNN Network Summer Virtual Event will take place on August 17-19, 2021, where 60 SmallCap, MicroCap and NanoCap public and private companies will be...

XXII : 0.1200 (-8.75%)
ACOG.VN : 0.240 (unch)
AYRO : 1.6700 (+0.60%)
BCDA : 0.4070 (-2.89%)
BLGO : 0.3549 (+4.57%)
BITF : 2.23 (+3.24%)
BITF.VN : 4.130 (+0.24%)
BAMM.CN : 0.0900 (-25.00%)
BMMJ : 0.0730 (-17.05%)
BCTX : 2.86 (+7.12%)
BCTXW : 1.3600 (+6.25%)
BCT.VN : 10.600 (-3.81%)
Orgenesis to Present at the SNN Network Summer Virtual Event on Thursday, August 19, 2021

GERMANTOWN, MD / ACCESSWIRE / August 12, 2021 / Orgenesis Inc. (NASDAQ:ORGS), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will be presenting...

ORGS : 0.8220 (-3.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing...

See More

Key Turning Points

3rd Resistance Point 0.8690
2nd Resistance Point 0.8595
1st Resistance Point 0.8407
Last Price 0.8220
1st Support Level 0.8124
2nd Support Level 0.8029
3rd Support Level 0.7841

See More

52-Week High 1.5000
Fibonacci 61.8% 1.0225
Fibonacci 50% 0.8750
Last Price 0.8220
Fibonacci 38.2% 0.7275
52-Week Low 0.2500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar